Report
Jon Berggren
EUR 923.90 For Business Accounts Only

Swedish Orphan Biovitrum (Buy, TP: SEK360.00) - This story goes deeper

Swedish Orphan Biovitrum’s best-in-class haemophilia products should ensure continued revenue growth in our forecast horizon, in our view. The magnitude of growth looks set to be determined by the company’s ramp-up in existing markets, supported by the outcome of post-approval trials. Moreover, Haemophilia revenues should allow Sobi to rebalance itself by expanding in Specialty Care. We initiate coverage with a BUY and SEK360 target price.
Underlying
Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB is a healthcare company focused on rare diseases. Co. develops, manufactures and commercializes treatments with a particular focus on four therapeutic areas: Inflammation, Genetics & Metabolism, Haemophilia and Neonatology. Co. also markets a portfolio of rare disease products for partner companies. Co.'s pipeline programmes include research and development focused on recombinant protein drugs in late preclinical and clinical phase for indications.

Provider
DnB Markets
DnB Markets

DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.

 

Analysts
Jon Berggren

Other Reports on these Companies
Other Reports from DnB Markets

ResearchPool Subscriptions

Get the most out of your insights

Get in touch